128 related articles for article (PubMed ID: 35946175)
1. ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma.
Shi Y; Shang J; Li Y; Zhong D; Zhang Z; Yang Q; Lai C; Feng T; Yao Y; Huang X
Cancer Med; 2023 Feb; 12(3):3786-3796. PubMed ID: 35946175
[TBL] [Abstract][Full Text] [Related]
2. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
3. CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.
Chen Z; Yuan T; Yan F; Ye S; Xie Q; Zhang B; Lin N; He Q; Yang B; Zhu H
BMC Cancer; 2022 Apr; 22(1):425. PubMed ID: 35440025
[TBL] [Abstract][Full Text] [Related]
4. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
Hashiba T; Yamashita T; Okada H; Nio K; Hayashi T; Asahina Y; Hayashi T; Terashima T; Iida N; Takatori H; Shimakami T; Kawaguchi K; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Takamura H; Ohta T; Honda M; Kaneko S
Cell Mol Gastroenterol Hepatol; 2020; 10(2):269-285. PubMed ID: 32169577
[TBL] [Abstract][Full Text] [Related]
6. Alpha7 nicotinic acetylcholine receptor expression in Sorafenib-resistant Hepatocellular carcinoma cells.
Nour MA; Kheradmand F; Rasmi Y; Baradaran B
Med Oncol; 2022 Aug; 39(11):165. PubMed ID: 35972579
[TBL] [Abstract][Full Text] [Related]
7. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
Li H; Gai L; Wu Z; Li F
Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864
[TBL] [Abstract][Full Text] [Related]
8. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
9. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
11. Implications of Withaferin A for the metastatic potential and drug resistance in hepatocellular carcinoma cells via Nrf2-mediated EMT and ferroptosis.
Zhang Y; Tan Y; Liu S; Yin H; Duan J; Fan L; Zhao X; Jiang B
Toxicol Mech Methods; 2023 Jan; 33(1):47-55. PubMed ID: 35592903
[TBL] [Abstract][Full Text] [Related]
12. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.
Yurdacan B; Egeli U; Guney Eskiler G; Eryilmaz IE; Cecener G; Tunca B
J Pharm Pharmacol; 2019 Jul; 71(7):1119-1132. PubMed ID: 31025377
[TBL] [Abstract][Full Text] [Related]
13. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
[No Abstract] [Full Text] [Related]
14. The role of daurisoline treatment in hepatocellular carcinoma: Inhibiting vasculogenic mimicry formation and enhancing sensitivity to sorafenib.
Zhang X; Zhang JG; Mu W; Zhou HM; Liu GL; Li Q
Phytomedicine; 2021 Nov; 92():153740. PubMed ID: 34600176
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B
Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430
[TBL] [Abstract][Full Text] [Related]
17. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
Makol A; Kaur H; Sharma S; Kanthaje S; Kaur R; Chakraborti A
Clin Mol Hepatol; 2020 Jan; 26(1):45-53. PubMed ID: 31564085
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1.
Jin W; Chen L; Cai X; Zhang Y; Zhang J; Ma D; Cai X; Fu T; Yu Z; Yu F; Chen G
Oncol Rep; 2017 Jan; 37(1):273-280. PubMed ID: 27878301
[TBL] [Abstract][Full Text] [Related]
19. [Establishment and gene expression analysis of drug-resistant cell lines in hepatocellular carcinoma induced by sorafenib].
Ma B; Tian ZH; Qu L; Liu YX; Zhang H; Ding HR
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):207-213. PubMed ID: 32306000
[TBL] [Abstract][Full Text] [Related]
20. Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinoma.
Cai J; Chen J; Wu T; Cheng Z; Tian Y; Pu C; Shi W; Suo X; Wu X; Zhang K
Biochem Biophys Res Commun; 2020 Jun; 526(4):1170-1176. PubMed ID: 32312520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
